PT3385252T - Moduladores de recetores canabinoides - Google Patents
Moduladores de recetores canabinoidesInfo
- Publication number
- PT3385252T PT3385252T PT181597386T PT18159738T PT3385252T PT 3385252 T PT3385252 T PT 3385252T PT 181597386 T PT181597386 T PT 181597386T PT 18159738 T PT18159738 T PT 18159738T PT 3385252 T PT3385252 T PT 3385252T
- Authority
- PT
- Portugal
- Prior art keywords
- receptor modulators
- cannabinoid receptor
- cannabinoid
- modulators
- receptor
- Prior art date
Links
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446729P | 2011-02-25 | 2011-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3385252T true PT3385252T (pt) | 2022-11-03 |
Family
ID=46000314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT181597386T PT3385252T (pt) | 2011-02-25 | 2012-02-24 | Moduladores de recetores canabinoides |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20140206649A1 (https=) |
| EP (2) | EP3385252B8 (https=) |
| JP (5) | JP6043733B2 (https=) |
| CN (2) | CN103492369B (https=) |
| AU (1) | AU2012222149B2 (https=) |
| DK (1) | DK3385252T3 (https=) |
| ES (1) | ES2929977T3 (https=) |
| IL (2) | IL227779A0 (https=) |
| MX (2) | MX392150B (https=) |
| PT (1) | PT3385252T (https=) |
| WO (1) | WO2012116279A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2770866C (en) * | 2009-08-28 | 2017-10-10 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| US9458136B2 (en) | 2011-02-25 | 2016-10-04 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
| CN103492369B (zh) | 2011-02-25 | 2019-03-29 | 艾尼纳制药公司 | 大麻素受体调节剂 |
| US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CA3019842A1 (en) * | 2016-04-10 | 2017-10-19 | Arena Pharmaceuticals, Inc. | Methods of treatment with selective cb2 receptor agonists |
| EP3621619B1 (en) | 2017-05-08 | 2023-06-28 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of visceral pain |
| CN114391011A (zh) * | 2019-09-12 | 2022-04-22 | 四川海思科制药有限公司 | 一种六氢化苯并吡唑衍生物及其制备 |
| WO2021047583A1 (zh) * | 2019-09-12 | 2021-03-18 | 四川海思科制药有限公司 | 一种三环吡唑衍生物及其制备 |
| CN112055360B (zh) * | 2020-09-07 | 2024-09-17 | 中兴通讯股份有限公司 | 资源确定、配置方法、装置、通信节点及存储介质 |
| US20250127789A1 (en) | 2021-11-04 | 2025-04-24 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US20250340570A1 (en) | 2022-04-27 | 2025-11-06 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US20250304593A1 (en) | 2022-05-12 | 2025-10-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US236010A (en) | 1880-12-28 | Wilhelm effer | ||
| US5605906A (en) | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| US7308894B2 (en) | 1998-06-03 | 2007-12-18 | Scott Laboratories, Inc. | Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics |
| NZ515086A (en) | 1999-04-28 | 2003-10-31 | Aventis Pharma Gmbh | Di-aryl acid derivatives as PPAR receptor ligands |
| AU2002357114B2 (en) | 2001-12-07 | 2008-07-24 | Virginia Commonwealth University | Treatment of neoplasia |
| IL150302A (en) | 2002-01-31 | 2008-07-08 | Naim Menashe | Bicyclic cb2 cannabinoid receptor ligands |
| SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| JP2008505965A (ja) * | 2004-07-12 | 2008-02-28 | カディラ ヘルスケア リミティド | カンナビノイド受容体修飾因子としての三環式ピラゾール誘導体 |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| CA2613678A1 (en) * | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US7597910B2 (en) | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
| WO2007035945A1 (en) * | 2005-09-23 | 2007-03-29 | Janssen Pharmaceutica, N.V. | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| PT2081572E (pt) | 2006-07-04 | 2010-05-17 | Janssen Pharmaceutica Nv | Agonistas de canabinóides de benzimidazolo com um grupo heterocíclico substituído |
| CA2664310A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| WO2008063781A2 (en) | 2006-10-12 | 2008-05-29 | Abbott Laboratories | Chemical compounds as cannabinoid receptor ligands |
| WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
| WO2008053341A2 (en) | 2006-11-03 | 2008-05-08 | Glenmark Pharmaceuticals S.A. | Bridged bicyclic indazoles as cannabinoid receptor ligands |
| WO2008064054A2 (en) | 2006-11-21 | 2008-05-29 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| US9763894B2 (en) | 2006-12-05 | 2017-09-19 | Virginia Commonwealth University | Inflammation therapy |
| US20080161340A1 (en) | 2006-12-20 | 2008-07-03 | Cara Therapeutics, Inc. | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof |
| WO2008085302A1 (en) | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| US20080214537A1 (en) | 2007-03-02 | 2008-09-04 | Cara Therapeutics, Inc. | Bridged phenanthridines |
| ES2548764T3 (es) | 2007-03-30 | 2015-10-20 | Janssen Pharmaceutica N.V. | Agonistas de cannabinoides de bencimidazol |
| US20090209536A1 (en) | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| EP2170350B1 (en) | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| EP2203171A2 (en) | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| UA104010C2 (en) | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| KR101787116B1 (ko) * | 2009-01-28 | 2017-10-18 | 케러 테라퓨틱스, 인코포레이티드 | 바이시클릭 피라졸로-헤테로사이클 |
| US7741350B1 (en) | 2009-01-28 | 2010-06-22 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| CA2770866C (en) * | 2009-08-28 | 2017-10-10 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| CN103492369B (zh) | 2011-02-25 | 2019-03-29 | 艾尼纳制药公司 | 大麻素受体调节剂 |
| US9458136B2 (en) * | 2011-02-25 | 2016-10-04 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
| US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2012116278A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
-
2012
- 2012-02-24 CN CN201280020334.4A patent/CN103492369B/zh not_active Expired - Fee Related
- 2012-02-24 JP JP2013555599A patent/JP6043733B2/ja not_active Expired - Fee Related
- 2012-02-24 CN CN201910180370.0A patent/CN109970708B/zh not_active Expired - Fee Related
- 2012-02-24 US US14/001,131 patent/US20140206649A1/en not_active Abandoned
- 2012-02-24 DK DK18159738.6T patent/DK3385252T3/da active
- 2012-02-24 EP EP18159738.6A patent/EP3385252B8/en active Active
- 2012-02-24 EP EP12716763.3A patent/EP2678318A1/en not_active Withdrawn
- 2012-02-24 MX MX2017003054A patent/MX392150B/es unknown
- 2012-02-24 MX MX2013009764A patent/MX346644B/es active IP Right Grant
- 2012-02-24 PT PT181597386T patent/PT3385252T/pt unknown
- 2012-02-24 ES ES18159738T patent/ES2929977T3/es active Active
- 2012-02-24 AU AU2012222149A patent/AU2012222149B2/en not_active Ceased
- 2012-02-24 WO PCT/US2012/026517 patent/WO2012116279A1/en not_active Ceased
-
2013
- 2013-08-04 IL IL227779A patent/IL227779A0/en unknown
-
2015
- 2015-12-02 US US14/956,586 patent/US9492447B2/en active Active
-
2016
- 2016-09-12 IL IL247779A patent/IL247779A/en active IP Right Grant
- 2016-09-29 US US15/279,576 patent/US9867822B2/en not_active Expired - Fee Related
- 2016-11-14 JP JP2016221615A patent/JP2017039773A/ja not_active Withdrawn
-
2017
- 2017-12-05 US US15/831,742 patent/US20180280386A1/en not_active Abandoned
-
2018
- 2018-06-01 JP JP2018106019A patent/JP2018162260A/ja not_active Withdrawn
-
2019
- 2019-06-17 US US16/442,734 patent/US20200069681A1/en not_active Abandoned
-
2020
- 2020-02-21 JP JP2020028389A patent/JP2020079302A/ja not_active Withdrawn
-
2021
- 2021-09-17 US US17/478,274 patent/US11771695B2/en active Active
-
2022
- 2022-02-28 JP JP2022029449A patent/JP2022066289A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227779A0 (en) | Cannabinoid receptor modulators | |
| PT2663550T (pt) | Benzoazepinas substítuidas utilizáveis como moduladores dos recetores tipo toll | |
| PL2663555T3 (pl) | Podstawione benzoazepiny jako modulatory receptora toll-podobnego | |
| SG11201401776WA (en) | Nmda receptor modulators and uses thereof | |
| AP3338A (en) | Glucagon receptor modulator | |
| GB201213700D0 (en) | Receptor antagnists II | |
| IL218130A0 (en) | Cannabinoid receptor modulators | |
| GB201004739D0 (en) | Receptor modulators | |
| ZA201406390B (en) | Liver x receptor modulators | |
| SG11201401794YA (en) | Selective androgen receptor modulators | |
| ZA201406326B (en) | Liver x receptor modulators | |
| IL235557B (en) | Modulators of 17 gpr receptors | |
| ZA201308942B (en) | Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators | |
| IL239076A0 (en) | Novel and selective androgen receptor modulators | |
| ZA201303950B (en) | Glucagon receptor modulators | |
| GB201223053D0 (en) | Receptor | |
| HK1192550A (en) | Cannabinoid receptor modulators | |
| HK1196825A (en) | Selective androgen receptor modulators |